Project cooperationUpdated on 27 August 2024
Mesoporous silica nanoparticles for immunoglobulin purification
Innovation and Technology Transfer Manager at IBIMA Plataforma BIONAND
Málaga, Spain
About
Currently, commercial systems for the purification of immunoglobulin G (IgG) use G-protein bound particles or resins with inunoglobulin binding capacity.
However, one of the main problems in affinity purification is the performance that the resins or particles offer to the user. Currently, commercial products show binding capacity ranging from 6 μg Ig/mg of material to 125 μg IgG/mg of material.
To improve this performance, the research group has developed protein G-bonded mesoporous silica particles with a given particle and pore size that allow increasing the binding capacity of immunoglobulins to the particles.
Tests have shown an IgG uptake capacity of between 460-800 μg of IgG per mg of nanoparticles, representing at least a 4-fold improvement over the best performing commercial product.
The production system also allows obtaining nanoparticles of highly homogeneous particle size and pore size.
Stage
- Early
Type
- Sales/Distribution
- Financing
Attached files
Similar opportunities
Product
Mesoporous silica nanoparticles and their use in the diagnosis of allergies
- Other
- Health innovation
- Pharmaceutical industry
Ana Somé
Technology Transfer Manager - Specialist on Intellectual Property at Universidad de Málaga
Málaga, Spain
Service
RAMON JOSE MARTINEZ MARTIN
Head of Pharma Sales - Iberia at Labanalysis Life Science S.r.l.
Barcelona, Italy
Product
NON-BINDING POLYSTYRENE MICROPLATES
- Other
- Cosmetic industry
- Health innovation
- Distribution Partner
- Laboratory industry
- Pharmaceutical industry
Ángel Luis Caba Marchán
Inside Sales Representative at Greiner Bio-One España S.A.U. at Greiner Bio-One España S.A.U.
Madrid, Spain